ASX Announcements - Regeneus Ltd

2021

26 February 2021 – Half-Year Results and Business Update

26 February 2021 – Appendix 4D and Half-Year Report

25 February 2021 – Regeneus Company Update Investor Webcast Notification

25 February 2021 – Resignation of Non Executive Director Dr Alan Dunton

9 February 2021 – Regeneus to be granted new patent to target pain in Japan

5 February 2021 – Response to ASX Appendix 4C Query

5 February 2021 – Clarification on Quarterly Activity Report and Appendix 4C

29 January 2021 – Appendix 4C – Quarterly Report

2020

19 November 2020 – Lapse of Unlisted Share Options

19 November 2020 – Appendix 3Y – Leo Lee

19 November 2020 – Appendix 3Y – Alan Dunton

19 November 2020 – Appendix 3Y – John Chiplin

19 November 2020 – Appendix 3Y – Graham Vesey

11 November 2020 – Clarification on Quarterly Activity Report and Appendix 4C

2 November 2020 – Material Terms of Contract for Chief Executive Officer

2 November 2020 – CEO Appointment and Resignation

30 October 2020 – Annual Report Additional Information

30 October 2020 – Appendix 4C – Quarterly

29 October 2020 – Regeneus receives $5.6M milestone payment from Kyocera

14 October 2020 – Results of Annual General Meeting

14 October 2020 – AGM Chairman’s Address and CEO Presentation

7 October 2020 – Regeneus to be granted new Sygenus patent in Canada

1 October 2020 – Australian Biomarker Patent Allowed

29 September 2020 – Regeneus receives $676k in R&D Tax Incentives

11 September 2020 – Notice of initial substantial holder – AGC Inc.

11 September 2020 – Virtual Annual General Meeting Online Guide

11 September 2020 – Notice of Annual General Meeting / Proxy / Question Form

10 September 2020 – Issue of AGC shares complete

10 September 2020 – Appendix 2A

10 September 2020 – Cleansing Notice

8 September 2020 – Notice of initial substantial holder – Kirman 2 Pty Ltd

3 September 2020 – Appendix 3G

3 September 2020 – Appendix 3Y – Leo Lee

3 September 2020 – CEO bonus payment

28 August 2020 – Regeneus receives milestone payment from Kyocera

28 August 2020 – Appendix 4G and Corporate Governance Statement

28 August 2020 – Appendix 4E and Annual Report

25 August 2020 – Regeneus to present at FNN Virtual Investor Event

19 August 2020 – Regeneus to be granted new Sygenus patent in US

11 August 2020 – Regeneus and Kyocera sign Progenza OA deal

7 August 2020 – Trading Halt

5 August 2020 – Date of AGM

31 July 2020 – Appendix 4C – Quarterly

28 July 2020 – Progenza OA licence with Kyocera enters final negotiation phase

6 July 2020 – Appendix 3G

4 June 2020 – Appendix 3Z – Final Director’s Interest Notice

4 June 2020 – Director Resignation

18 May 2020 – Kyocera completes Progenza Due Diligence

5 May 2020 – Appendix 4C – Quarterly (Updated)

29 April 2020 – Appendix 4C – Quarterly

1 April 2020 – Appendix 3G

23 March 2020 – Regeneus to be granted new key Progenza patent in U.S.

20 March 2020 – Regeneus receives A$1.6M milestone payment from Kyocera

2 March 2020 – Regeneus signs MOU agreement with Kyocera on exclusive negotiation rights for Progenza in Japan

28 February 2020 – Half-Year Results & Business Update

28 February 2020 – Appendix 4D and Half-Year Report

28 February 2020 – Directors provide $4M loan to support commercial license discussions

6 February 2020 – ASX Response Letter & 3Ys

6 February 2020 – Appendix 3G

31 January 2020 – Appendix 4C – Quarterly

20 January 2020 – Appendix 3G

2019

20 December 2019 – Proposed issue of Securities – RGS

20 December 2019 – AGC Agreement termination paves way for commercial partner

18 December 2019 – RGS receives Innovation Grant

21 November 2019 – Results of the Annual General Meeting

21 November 2019 – CEO Presentation to 2019 Annual General Meeting

21 November 2019 – Chairman’s Address to Shareholders

20 November 2019 – Cleansing Statement

20 November 2019 – Appendix 3B

19 November 2019 – Japanese Biotech Fund takes up all Rights Issue Shortfall

31 October 2019 – Response to ASX Appendix 4C Query

31 October 2019 – Appendix 4C – Quarterly

30 October 2019 – Appendix 4G and Corporate Governance Statement

30 October 2019 – Annual Report 2019

19 October 2019 – Change of Registered Office and Principal Place of Business

18 October 2019 – Notice of Annual General Meeting / Proxy Form

15 October 2019 – Regeneus receives A$1.5 million in R&D Tax Incentives

26 September 2019 – Financial Report – Year Ended 30 June 2019

11 September 2019 – Notice of initial substantial holder – Leo Lee

11 September 2019 – Change of interests of substantial holder – Graham Vesey

10 September 2019 – Date of AGM

3 September 2019 – Appendix 3Y – Barry Sechos

3 September 2019 – Appendix 3Y – Leo Lee

3 September 2019 – Appendix 3Y – Glen Richards

3 September 2019 – Appendix 3B

30 August 2019 – Rights Issue Shortfall Notice

30 August 2019 – Clarification to announcement

30 August 2019 – Appendix 4E

13 August 2019 – Confirmation of Despatch of Offer Booklet

13 August 2019 – Restructuring results in 50% reduction in operating costs

7 August 2019 – Updated Investor Presentation

7 August 2019 – Placement Appendix 3B and Cleansing Statement

2 August 2019 – Letter to Shareholders – Non Renounceable Rights Issue

1 August 2019 – Investor Presentation

1 August 2019 – Letter to Option holders

1 August 2019 – Offer Booklet

1 August 2019 – Cleansing Notice

1 August 2019 – Successful Private Placement

1 August 2019 – Appendix 3B

31 July 2019 – Appendix 4C – Quarterly

30 July 2019 – Trading Halt

23 July 2019 – Positive results for Progenza in treating neuropathic pain

22 July 2019 – New Strategy To Deliver Therapies For Global Pain Market

2 May 2019 – Appendix 3Z – Final Director Interest Notice

2 May 2019 – Appendix 3X – Initial Director Interest Notice

29 April 2019 – Regeneus Appoints International Directors for Global Growth

11 April 2019 – Appendix 4C – Quarterly

28 February 2019 – Appendix 4D and Half-Year Report

28 February 2019 – Directors Provide $2.5M Loan to Extend Funding Runway

2 February 2019 – Response to ASX Appendix 4C Query Letter

2 February 2019 – Material Terms of Contract for Chief Executive Officer

30 January 2019 – Appendix 4C – Quarterly

23 January 2019 – New CEO Appointed to Accelerate Global Growth

See the full archive